Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial-Reference-Cited by-同舟云学术

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

Published:2020-09 Issue:9 Volume:8 Page:895-904
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Middleton Gary,Brock Kristian,Savage Joshua,Mant Rhys,Summers Yvonne,Connibear John,Shah Riyaz,Ottensmeier Christian,Shaw Paul,Lee Siow-Ming,Popat Sanjay,Barrie Colin,Barone Gloria,Billingham Lucinda

Funder

Experimental Cancer Medicine Centres

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference24 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

2. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study;Garon;J Clin Oncol,2019

3. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

4. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

5. Toxicity and response criteria of the Eastern Cooperative Oncology Group;Oken;Am J Clin Oncol,1982

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials;Cancer Treatment Reviews;2024-09

2. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database;Journal of Geriatric Oncology;2024-09

3. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer;Journal of Translational Medicine;2024-08-21

4. Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.;Journal of Chemotherapy;2024-08-06

5. Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data;Discover Oncology;2024-07-24